{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T00:29:01Z","timestamp":1794011341697,"version":"4.8.0"},"reference-count":194,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["T32AR007080-44S1"],"award-info":[{"award-number":["T32AR007080-44S1"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40265-026-02339-5","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T17:15:15Z","timestamp":1780593315000},"page":"1307-1324","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Classic Psychedelics for Chronic Pain: A Critical Review of the Literature and Practical Advice for Clinicians"],"prefix":"10.1007","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3696-3979","authenticated-orcid":false,"given":"Kevin F.","family":"Boehnke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niloufar","family":"Pouyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob S.","family":"Aday","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"2339_CR1","unstructured":"Zelaya CE, Dahlhamer JM, Lucas JW, Connor EM. Chronic pain and high-impact chronic pain among US adults, 2019. In: Prevention CfDCa, editor; 2020."},{"issue":"10289","key":"2339_CR2","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1016\/S0140-6736(21)00393-7","volume":"397","author":"SP Cohen","year":"2021","unstructured":"Cohen SP, Vase L, Hooten WM. Chronic pain: an update on burden, best practices, and new advances. Lancet. 2021;397(10289):2082\u201397.","journal-title":"Lancet"},{"key":"2339_CR3","volume-title":"Relieving pain in America: a blueprint for transforming prevention, care, education, and research","author":"Institute of M","year":"2011","unstructured":"Institute of M, Medicine Io, Institute of M. Relieving pain in America: a blueprint for transforming prevention, care, education, and research. Washington, DC: The National Academies Press; 2011."},{"issue":"7","key":"2339_CR4","doi-asserted-by":"publisher","first-page":"480","DOI":"10.7326\/M16-2458","volume":"166","author":"R Chou","year":"2017","unstructured":"Chou R, Deyo R, Friedly J, Skelly A, Weimer M, Fu R, et al. Systemic pharmacologic therapies for low back pain: a systematic review for an American College of Physicians clinical practice guideline. Ann Intern Med. 2017;166(7):480\u201392.","journal-title":"Ann Intern Med"},{"issue":"2","key":"2339_CR5","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","volume":"14","author":"NB Finnerup","year":"2015","unstructured":"Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162\u201373.","journal-title":"Lancet Neurol"},{"issue":"6","key":"2339_CR6","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jpain.2010.01.002","volume":"11","author":"W Hauser","year":"2010","unstructured":"Hauser W, Petzke F, Sommer C. Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome. J Pain. 2010;11(6):505\u201321.","journal-title":"J Pain"},{"issue":"4","key":"2339_CR7","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/j.1532-2149.2012.00234.x","volume":"17","author":"F Wolfe","year":"2013","unstructured":"Wolfe F, Walitt BT, Katz RS, Lee YC, Michaud KD, Hauser W. Longitudinal patterns of analgesic and central acting drug use and associated effectiveness in fibromyalgia. Eur J Pain. 2013;17(4):581\u20136.","journal-title":"Eur J Pain"},{"issue":"21","key":"2339_CR8","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1001\/jama.2018.17722","volume":"320","author":"KF Boehnke","year":"2018","unstructured":"Boehnke KF. Pain management: assembling a tool kit, building a life. JAMA. 2018;320(21):2201\u20132.","journal-title":"JAMA"},{"key":"2339_CR9","doi-asserted-by":"publisher","DOI":"10.1177\/20494637251319497","author":"NG Glynos","year":"2025","unstructured":"Glynos NG, Baker A, Aday JS, Kruger D, Boehnke KF, Lake S, et al. Psychedelics and chronic pain: Self-reported outcomes on changed substance use patterns and health following naturalistic psychedelic use. Br J Pain. 2025. https:\/\/doi.org\/10.1177\/20494637251319497.","journal-title":"Br J Pain"},{"key":"2339_CR10","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/7854_2016_459","volume":"36","author":"KH Preller","year":"2018","unstructured":"Preller KH, Vollenweider FX. Phenomenology, structure, and dynamic of psychedelic states. Curr Top Behav Neurosci. 2018;36:221\u201356.","journal-title":"Curr Top Behav Neurosci"},{"issue":"5","key":"2339_CR11","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1515\/revneuro-2020-0094","volume":"32","author":"JS Aday","year":"2021","unstructured":"Aday JS, Wood JR, Bloesch EK, Davoli CC. Psychedelic drugs and perception: a narrative review of the first era of research. Rev Neurosci. 2021;32(5):559\u201371.","journal-title":"Rev Neurosci"},{"issue":"1","key":"2339_CR12","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1213\/ANE.0000000000004185","volume":"129","author":"V Orhurhu","year":"2019","unstructured":"Orhurhu V, Orhurhu MS, Bhatia A, Cohen SP. Ketamine infusions for chronic pain: a systematic review and meta-analysis of randomized controlled trials. Anesth Analg. 2019;129(1):241\u201354.","journal-title":"Anesth Analg"},{"key":"2339_CR13","doi-asserted-by":"publisher","first-page":"1022767","DOI":"10.3389\/fpain.2022.1022767","volume":"3","author":"A Balachandran","year":"2022","unstructured":"Balachandran A, Tassone VK, Adamsahib F, Di Passa AM, Kuburi S, Demchenko I, et al. Efficacy of ketamine for comorbid depression and acute or chronic pain: a systematic review. Front Pain Res (Lausanne). 2022;3:1022767.","journal-title":"Front Pain Res (Lausanne)."},{"issue":"3","key":"2339_CR14","doi-asserted-by":"publisher","first-page":"e185","DOI":"10.1016\/j.jpainsymman.2023.11.004","volume":"67","author":"J Jiao","year":"2024","unstructured":"Jiao J, Fan J, Zhang Y, Chen L. Efficacy and safety of ketamine to treat cancer pain in adult patients: a systematic review. J Pain Symptom Manage. 2024;67(3):e185\u2013210.","journal-title":"J Pain Symptom Manage"},{"key":"2339_CR15","doi-asserted-by":"publisher","first-page":"1338581","DOI":"10.3389\/fpsyt.2024.1338581","volume":"15","author":"JJW Liu","year":"2024","unstructured":"Liu JJW, Ein N, Gervasio J, Baker C, Plouffe R, Wanklyn S, et al. Ketamine in the effective management of chronic pain, depression, and posttraumatic stress disorder for Veterans: a meta-analysis and systematic review. Front Psychiatry. 2024;15:1338581.","journal-title":"Front Psychiatry."},{"key":"2339_CR16","unstructured":"Delgado J, Traub S, Gayzel J. Intoxication from LSD and other common hallucinogens. UpToDate. 2017."},{"issue":"2","key":"2339_CR17","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.pharmthera.2003.11.002","volume":"101","author":"DE Nichols","year":"2004","unstructured":"Nichols DE. Hallucinogens. Pharmacol Ther. 2004;101(2):131\u201381.","journal-title":"Pharmacol Ther"},{"key":"2339_CR18","volume-title":"The psychedelic handbook: a practical guide to psilocybin, LSD, ketamine, MDMA, and Ayahuasca","author":"R Strassman","year":"2022","unstructured":"Strassman R. The psychedelic handbook: a practical guide to psilocybin, LSD, ketamine, MDMA, and Ayahuasca. New York: Simon and Schuster; 2022."},{"key":"2339_CR19","volume-title":"Disposition of toxic drugs and chemicals in man","author":"RC Baselt","year":"1982","unstructured":"Baselt RC, Cravey RH. Disposition of toxic drugs and chemicals in man. Davis, CA: Biomedical publications; 1982."},{"key":"2339_CR20","unstructured":"Administration DE. Drugs of abuse, a DEA resource guide, 2024 edition. In: US Department of Justice, editor; 2024."},{"key":"2339_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.1040217","volume":"13","author":"CA MacCallum","year":"2022","unstructured":"MacCallum CA, Lo LA, Pistawka CA, Deol JK. Therapeutic use of psilocybin: practical considerations for dosing and administration. Front Psychiatry. 2022;13:1040217.","journal-title":"Front Psychiatry"},{"issue":"10","key":"2339_CR22","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s40263-022-00944-y","volume":"36","author":"N Pouyan","year":"2022","unstructured":"Pouyan N, Halvaei Khankahdani Z, Younesi Sisi F, Lee Y, Rosenblat JD, Teopiz KM, et al. A Research Domain Criteria (RDoC)-guided dashboard to review psilocybin target domains: a systematic review. CNS Drugs. 2022;36(10):1031\u201347.","journal-title":"CNS Drugs"},{"issue":"12","key":"2339_CR23","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s40263-023-01044-1","volume":"37","author":"N Pouyan","year":"2023","unstructured":"Pouyan N, Younesi Sisi F, Kargar A, Scheidegger M, McIntyre RS, Morrow JD. The effects of lysergic acid diethylamide (LSD) on the positive valence systems: a Research Domain Criteria (RDoC)-informed systematic review. CNS Drugs. 2023;37(12):1027\u201363.","journal-title":"CNS Drugs"},{"issue":"6","key":"2339_CR24","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1001\/jamapsychiatry.2023.0549","volume":"80","author":"JS Aday","year":"2023","unstructured":"Aday JS, Carhart-Harris RL, Woolley JD. Emerging challenges for psychedelic therapy. JAMA Psychiat. 2023;80(6):533\u20134.","journal-title":"JAMA Psychiat"},{"issue":"3","key":"2339_CR25","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s12276-025-01409-0","volume":"57","author":"NJ Jayathilake","year":"2025","unstructured":"Jayathilake NJ, Phan TT, Kim J, Lee KP, Park JM. Modulating neuroplasticity for chronic pain relief: noninvasive neuromodulation as a promising approach. Exp Mol Med. 2025;57(3):501\u201314.","journal-title":"Exp Mol Med"},{"key":"2339_CR26","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/4842159","volume":"2016","author":"XY Li","year":"2016","unstructured":"Li XY, Wan Y, Tang SJ, Guan Y, Wei F, Ma D. Maladaptive plasticity and neuropathic pain. Neural Plast. 2016;2016:4842159.","journal-title":"Neural Plast"},{"issue":"4","key":"2339_CR27","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1080\/09540261.2018.1481827","volume":"30","author":"TW Flanagan","year":"2018","unstructured":"Flanagan TW, Nichols CD. Psychedelics as anti-inflammatory agents. Int Rev Psychiatry. 2018;30(4):363\u201375.","journal-title":"Int Rev Psychiatry"},{"issue":"4","key":"2339_CR28","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00221-013-3579-0","volume":"228","author":"BJ Catlow","year":"2013","unstructured":"Catlow BJ, Song S, Paredes DA, Kirstein CL, Sanchez-Ramos J. Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning. Exp Brain Res. 2013;228(4):481\u201391.","journal-title":"Exp Brain Res"},{"issue":"16","key":"2339_CR29","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1016\/j.neuron.2021.06.008","volume":"109","author":"L-X Shao","year":"2021","unstructured":"Shao L-X, Liao C, Gregg I, Davoudian PA, Savalia NK, Delagarza K, et al. Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. Neuron. 2021;109(16):2535-44. e4.","journal-title":"Neuron"},{"key":"2339_CR30","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.bbi.2023.09.004","volume":"114","author":"N Mason","year":"2023","unstructured":"Mason N, Szabo A, Kuypers K, Mallaroni P, De La Torre FR, Reckweg J, et al. Psilocybin induces acute and persisting alterations in immune status in healthy volunteers: an experimental, placebo-controlled study. Brain Behav Immun. 2023;114:299\u2013310.","journal-title":"Brain Behav Immun"},{"issue":"11","key":"2339_CR31","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.1016\/j.celrep.2018.05.022","volume":"23","author":"C Ly","year":"2018","unstructured":"Ly C, Greb AC, Cameron LP, Wong JM, Barragan EV, Wilson PC, et al. Psychedelics promote structural and functional neural plasticity. Cell Rep. 2018;23(11):3170\u201382.","journal-title":"Cell Rep"},{"key":"2339_CR32","doi-asserted-by":"crossref","unstructured":"Calder AE, Hasler G. Towards an understanding of psychedelic-induced neuroplasticity. Neuropsychopharmacology. 2022.","DOI":"10.1038\/s41386-022-01389-z"},{"issue":"2","key":"2339_CR33","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3390\/ijms22020835","volume":"22","author":"NR Raval","year":"2021","unstructured":"Raval NR, Johansen A, Donovan LL, Ros NF, Ozenne B, Hansen HD, et al. A single dose of psilocybin increases synaptic density and decreases 5-HT2A receptor density in the pig brain. Int J Mol Sci. 2021;22(2):835.","journal-title":"Int J Mol Sci"},{"key":"2339_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-025-03257-w","author":"TG Ekins","year":"2025","unstructured":"Ekins TG, Rybicki-Kler C, Deng T, Brooks IA, Jedrasiak-Cape I, Donoho E, et al. Psychedelic neuroplasticity of cortical neurons lacking 5-HT2A receptors. Mol Psychiatry. 2025. https:\/\/doi.org\/10.1038\/s41380-025-03257-w.","journal-title":"Mol Psychiatry"},{"issue":"6633","key":"2339_CR35","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1126\/science.adf0435","volume":"379","author":"MV Vargas","year":"2023","unstructured":"Vargas MV, Dunlap LE, Dong C, Carter SJ, Tombari RJ, Jami SA, et al. Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors. Science. 2023;379(6633):700\u20136.","journal-title":"Science"},{"issue":"8","key":"2339_CR36","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1523\/JNEUROSCI.17-08-02785.1997","volume":"17","author":"VA Vaidya","year":"1997","unstructured":"Vaidya VA, Marek GJ, Aghajanian GK, Duman RS. 5-HT2A receptor-mediated regulation of brain-derived neurotrophic factor mRNA in the hippocampus and the neocortex. J Neurosci. 1997;17(8):2785\u201395.","journal-title":"J Neurosci"},{"issue":"6","key":"2339_CR37","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1038\/s41593-023-01316-5","volume":"26","author":"R Moliner","year":"2023","unstructured":"Moliner R, Girych M, Brunello CA, Kovaleva V, Biojone C, Enkavi G, et al. Psychedelics promote plasticity by directly binding to BDNF receptor TrkB. Nat Neurosci. 2023;26(6):1032\u201341.","journal-title":"Nat Neurosci"},{"issue":"2","key":"2339_CR38","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/s41380-024-02830-z","volume":"30","author":"AE Calder","year":"2025","unstructured":"Calder AE, Hase A, Hasler G. Effects of psychoplastogens on blood levels of brain-derived neurotrophic factor (BDNF) in humans: a systematic review and meta-analysis. Mol Psychiatry. 2025;30(2):763\u201376.","journal-title":"Mol Psychiatry"},{"issue":"6","key":"2339_CR39","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1097\/ALN.0000000000000017","volume":"119","author":"RE Harris","year":"2013","unstructured":"Harris RE, Napadow V, Huggins JP, Pauer L, Kim J, Hampson J, et al. Pregabalin rectifies aberrant brain chemistry, connectivity, and functional response in chronic pain patients. Anesthesiology. 2013;119(6):1453\u201364.","journal-title":"Anesthesiology"},{"issue":"2","key":"2339_CR40","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/cpt.557","volume":"101","author":"DE Nichols","year":"2017","unstructured":"Nichols DE, Johnson MW, Nichols CD. Psychedelics as medicines: an emerging new paradigm. Clin Pharmacol Ther. 2017;101(2):209\u201319.","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"2339_CR41","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","volume":"30","author":"RR Griffiths","year":"2016","unstructured":"Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. 2016;30(12):1181\u201397.","journal-title":"J Psychopharmacol"},{"key":"2339_CR42","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3389\/fphar.2018.00256","volume":"9","author":"TC Malone","year":"2018","unstructured":"Malone TC, Mennenga SE, Guss J, Podrebarac SK, Owens LT, Bossis AP, et al. Individual experiences in four cancer patients following psilocybin-assisted psychotherapy. Front Pharmacol. 2018;9:256.","journal-title":"Front Pharmacol"},{"issue":"8","key":"2339_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0271926","volume":"17","author":"MM Sweeney","year":"2022","unstructured":"Sweeney MM, Nayak S, Hurwitz ES, Mitchell LN, Swift TC, Griffiths RR. Comparison of psychedelic and near-death or other non-ordinary experiences in changing attitudes about death and dying. PLoS ONE. 2022;17(8):e0271926.","journal-title":"PLoS ONE"},{"issue":"5","key":"2339_CR44","doi-asserted-by":"publisher","DOI":"10.1192\/bjo.2022.565","volume":"8","author":"T Barba","year":"2022","unstructured":"Barba T, Buehler S, Kettner H, Radu C, Cunha BG, Nutt DJ, et al. Effects of psilocybin versus escitalopram on rumination and thought suppression in depression. BJPsych Open. 2022;8(5):e163.","journal-title":"BJPsych Open."},{"issue":"1","key":"2339_CR45","first-page":"88","volume":"10","author":"B Fauvel","year":"2023","unstructured":"Fauvel B, Strika-Bruneau L, Piolino P. Changes in self-rumination and self-compassion mediate the effect of psychedelic experiences on decreases in depression, anxiety, and stress. Psychol Conscious Theor Res Pract. 2023;10(1):88.","journal-title":"Psychol Conscious Theor Res Pract"},{"key":"2339_CR46","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s00213-017-4701-y","volume":"235","author":"RL Carhart-Harris","year":"2018","unstructured":"Carhart-Harris RL, Erritzoe D, Haijen E, Kaelen M, Watts R. Psychedelics and connectedness. Psychopharmacology. 2018;235:547\u201350.","journal-title":"Psychopharmacology"},{"issue":"5","key":"2339_CR47","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1073\/pnas.1918477117","volume":"117","author":"M Forstmann","year":"2020","unstructured":"Forstmann M, Yudkin DA, Prosser AM, Heller SM, Crockett MJ. Transformative experience and social connectedness mediate the mood-enhancing effects of psychedelic use in naturalistic settings. Proc Natl Acad Sci USA. 2020;117(5):2338\u201346.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"2339_CR48","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1177\/0269881117731279","volume":"32","author":"RR Griffiths","year":"2018","unstructured":"Griffiths RR, Johnson MW, Richards WA, Richards BD, Jesse R, MacLean KA, et al. Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. J Psychopharmacol. 2018;32(1):49\u201369.","journal-title":"J Psychopharmacol"},{"issue":"24","key":"2339_CR49","doi-asserted-by":"publisher","first-page":"R1282","DOI":"10.1016\/j.cub.2023.10.016","volume":"33","author":"N Kolbman","year":"2023","unstructured":"Kolbman N, Liu T, Guzzo P, Gilligan J, Mashour GA, Vanini G, et al. Intravenous psilocybin attenuates mechanical hypersensitivity in a rat model of chronic pain. Curr Biol. 2023;33(24):R1282\u20133.","journal-title":"Curr Biol"},{"issue":"11","key":"2339_CR50","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1038\/s41593-025-02068-0","volume":"28","author":"A Hammo","year":"2025","unstructured":"Hammo A, Wisser S, Cichon J. Single-dose psilocybin rapidly and sustainably relieves allodynia and anxiodepressive-like behaviors in mouse models of chronic pain. Nat Neurosci. 2025;28(11):2285\u201395.","journal-title":"Nat Neurosci"},{"key":"2339_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-026-68763-z","author":"NS Gregory","year":"2026","unstructured":"Gregory NS, Girard TE, Ram A, Casey AB, Malenka RC, Tawfik VL, et al. No evidence of immediate or persistent analgesic effect from a single dose of psilocybin in three mouse models of pain. Nat Commun. 2026. https:\/\/doi.org\/10.1038\/s41467-026-68763-z.","journal-title":"Nat Commun"},{"issue":"2","key":"2339_CR52","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1080\/02791072.2019.1606472","volume":"51","author":"RE Doblin","year":"2019","unstructured":"Doblin RE, Christiansen M, Jerome L, Burge B. The past and future of psychedelic science: an introduction to this issue. J Psychoactive Drugs. 2019;51(2):93\u20137.","journal-title":"J Psychoactive Drugs"},{"key":"2339_CR53","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.neuropharm.2018.02.018","volume":"142","author":"SJ Belouin","year":"2018","unstructured":"Belouin SJ, Henningfield JE. Psychedelics: where we are now, why we got here, what we must do. Neuropharmacology. 2018;142:7\u201319.","journal-title":"Neuropharmacology"},{"key":"2339_CR54","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s00213-006-0457-5","volume":"187","author":"RR Griffiths","year":"2006","unstructured":"Griffiths RR, Richards WA, McCann U, Jesse R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology Berl. 2006;187:268\u201383.","journal-title":"Psychopharmacology Berl"},{"key":"2339_CR55","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s00213-011-2358-5","volume":"218","author":"RR Griffiths","year":"2011","unstructured":"Griffiths RR, Johnson MW, Richards WA, Richards BD, McCann U, Jesse R. Psilocybin occasioned mystical-type experiences: Immediate and persisting dose-related effects. Psychopharmacology Berl. 2011;218:649\u201365.","journal-title":"Psychopharmacology Berl"},{"issue":"5","key":"2339_CR56","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","volume":"78","author":"AK Davis","year":"2021","unstructured":"Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, et al. Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiat. 2021;78(5):481\u20139.","journal-title":"JAMA Psychiat"},{"issue":"3","key":"2339_CR57","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1177\/0269881114565144","volume":"29","author":"MP Bogenschutz","year":"2015","unstructured":"Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PC, Strassman RJ. Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. J Psychopharmacol. 2015;29(3):289\u201399.","journal-title":"J Psychopharmacol"},{"issue":"7","key":"2339_CR58","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","volume":"3","author":"RL Carhart-Harris","year":"2016","unstructured":"Carhart-Harris RL, Bolstridge M, Rucker J, Day CM, Erritzoe D, Kaelen M, et al. Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study. Lancet Psychiatry. 2016;3(7):619\u201327.","journal-title":"Lancet Psychiatry"},{"issue":"5","key":"2339_CR59","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1007\/s00213-020-05477-0","volume":"237","author":"T Lea","year":"2020","unstructured":"Lea T, Amada N, Jungaberle H, Schecke H, Scherbaum N, Klein M. Perceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders. Psychopharmacology. 2020;237(5):1521\u201332.","journal-title":"Psychopharmacology"},{"issue":"15","key":"2339_CR60","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","volume":"384","author":"R Carhart-Harris","year":"2021","unstructured":"Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, et al. Trial of psilocybin versus escitalopram for depression. N Engl J Med. 2021;384(15):1402\u201311.","journal-title":"N Engl J Med"},{"key":"2339_CR61","doi-asserted-by":"crossref","unstructured":"Bogenschutz MP, Ross S, Bhatt S, Baron T, Forcehimes AA, Laska E, et al. Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry. 2022.","DOI":"10.1001\/jamapsychiatry.2022.2096"},{"issue":"9","key":"2339_CR62","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jama.2023.14530","volume":"330","author":"CL Raison","year":"2023","unstructured":"Raison CL, Sanacora G, Woolley J, Heinzerling K, Dunlop BW, Brown RT, et al. Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial. JAMA. 2023;330(9):843\u201353.","journal-title":"JAMA"},{"key":"2339_CR63","doi-asserted-by":"crossref","unstructured":"Aaronson ST, van der Vaart A, Miller T, LaPratt J, Swartz K, Shoultz A, et al. Single-dose synthetic psilocybin with psychotherapy for treatment-resistant bipolar type II major depressive episodes: a nonrandomized controlled trial. JAMA Psychiatry. 2023.","DOI":"10.1001\/jamapsychiatry.2023.4685"},{"key":"2339_CR64","doi-asserted-by":"publisher","DOI":"10.3389\/fpain.2025.1527783","volume":"6","author":"JS Aday","year":"2025","unstructured":"Aday JS, McAfee J, Conroy DA, Hosanagar A, Tarnal V, Weston C, et al. Preliminary safety and effectiveness of psilocybin-assisted therapy in adults with fibromyalgia: An open-label pilot clinical trial. Front Pain Res. 2025;6:1527783.","journal-title":"Front Pain Res"},{"key":"2339_CR65","doi-asserted-by":"publisher","first-page":"955","DOI":"10.3389\/fpsyt.2019.00955","volume":"10","author":"A Garcia-Romeu","year":"2019","unstructured":"Garcia-Romeu A, Davis AK, Erowid E, Erowid F, Griffiths RR, Johnson MW. Persisting reductions in cannabis, opioid, and stimulant misuse after naturalistic psychedelic use: an online survey. Front Psychiatry. 2019;10:955.","journal-title":"Front Psychiatry."},{"issue":"9","key":"2339_CR66","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1177\/0269881119845793","volume":"33","author":"A Garcia-Romeu","year":"2019","unstructured":"Garcia-Romeu A, Davis AK, Erowid F, Erowid E, Griffiths RR, Johnson MW. Cessation and reduction in alcohol consumption and misuse after psychedelic use. J Psychopharmacol. 2019;33(9):1088\u2013101.","journal-title":"J Psychopharmacol"},{"key":"2339_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2019.11.008","volume":"75","author":"T Lea","year":"2020","unstructured":"Lea T, Amada N, Jungaberle H, Schecke H, Klein M. Microdosing psychedelics: motivations, subjective effects and harm reduction. Int J Drug Policy. 2020;75:102600.","journal-title":"Int J Drug Policy"},{"issue":"6","key":"2339_CR68","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1177\/0269881120908004","volume":"34","author":"D Rosenbaum","year":"2020","unstructured":"Rosenbaum D, Weissman C, Anderson T, Petranker R, Dinh-Williams LA, Hui K, et al. Microdosing psychedelics: demographics, practices, and psychiatric comorbidities. J Psychopharmacol. 2020;34(6):612\u201322.","journal-title":"J Psychopharmacol"},{"key":"2339_CR69","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.647909","volume":"12","author":"K Mans","year":"2021","unstructured":"Mans K, Kettner H, Erritzoe D, Haijen E, Kaelen M, Carhart-Harris RL. Sustained, multifaceted improvements in mental well-being following psychedelic experiences in a prospective opportunity sample. Front Psychiatry. 2021;12:647909.","journal-title":"Front Psychiatry"},{"issue":"4","key":"2339_CR70","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1007\/s40519-020-01000-8","volume":"26","author":"MJ Spriggs","year":"2021","unstructured":"Spriggs MJ, Kettner H, Carhart-Harris RL. Positive effects of psychedelics on depression and wellbeing scores in individuals reporting an eating disorder. Eat Weight Disord. 2021;26(4):1265\u201370.","journal-title":"Eat Weight Disord"},{"key":"2339_CR71","doi-asserted-by":"publisher","DOI":"10.1177\/20494637221114962","author":"V Bonnelle","year":"2022","unstructured":"Bonnelle V, Smith WJ, Mason NL, Cavarra M, Kryskow P, Kuypers KPC, et al. Analgesic potential of macrodoses and microdoses of classical psychedelics in chronic pain sufferers: a population survey. Br J Pain. 2022. https:\/\/doi.org\/10.1177\/20494637221114962.","journal-title":"Br J Pain"},{"issue":"1","key":"2339_CR72","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/ejp.2171","volume":"28","author":"M Cavarra","year":"2024","unstructured":"Cavarra M, Mason NL, Kuypers KPC, Bonnelle V, Smith WJ, Feilding A, et al. Potential analgesic effects of psychedelics on select chronic pain conditions: a survey study. Eur J Pain. 2024;28(1):153\u201365.","journal-title":"Eur J Pain"},{"key":"2339_CR73","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.735427","volume":"12","author":"J Bornemann","year":"2021","unstructured":"Bornemann J, Close JB, Spriggs MJ, Carhart-Harris R, Roseman L. Self-medication for chronic pain using classic psychedelics: a qualitative investigation to inform future research. Front Psychiatry. 2021;12:1895.","journal-title":"Front Psychiatry"},{"key":"2339_CR74","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2021.2022817","author":"NG Glynos","year":"2022","unstructured":"Glynos NG, Pierce J, Davis AK, McAfee J, Boehnke KF. Knowledge, perceptions, and use of psychedelics among individuals with fibromyalgia. J Psychoactive Drugs. 2022. https:\/\/doi.org\/10.1080\/02791072.2021.2022817.","journal-title":"J Psychoactive Drugs"},{"key":"2339_CR75","doi-asserted-by":"publisher","DOI":"10.1007\/s11469-023-01085-z","author":"KF Boehnke","year":"2023","unstructured":"Boehnke KF, Kruger DJ, Lucas P. Changed substance use after psychedelic experiences among individuals in Canada. Int J Ment Heal Addict. 2023. https:\/\/doi.org\/10.1007\/s11469-023-01085-z.","journal-title":"Int J Ment Heal Addict"},{"key":"2339_CR76","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2024.1349565","volume":"15","author":"NG Glynos","year":"2024","unstructured":"Glynos NG, Aday JS, Kruger D, Boehnke KF, Lake S, Lucas P. Psychedelic substitution: altered substance use patterns following psychedelic use in a global survey. Front Psychiatry. 2024;15:1349565.","journal-title":"Front Psychiatry"},{"issue":"7","key":"2339_CR77","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1136\/rapm-2020-101273","volume":"45","author":"JP Castellanos","year":"2020","unstructured":"Castellanos JP, Woolley C, Bruno KA, Zeidan F, Halberstadt A, Furnish T. Chronic pain and psychedelics: a review and proposed mechanism of action. Reg Anesth Pain Med. 2020;45(7):486\u201394.","journal-title":"Reg Anesth Pain Med"},{"issue":"4","key":"2339_CR78","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1097\/j.pain.0000000000002778","volume":"164","author":"M Lyes","year":"2023","unstructured":"Lyes M, Yang KH, Castellanos J, Furnish T. Microdosing psilocybin for chronic pain: a case series. Pain. 2023;164(4):698\u2013702.","journal-title":"Pain"},{"key":"2339_CR79","doi-asserted-by":"publisher","DOI":"10.1177\/25158163251345472","author":"J Leighton","year":"2025","unstructured":"Leighton J, Lau C, Savdo A, Granata L. Clinical treatment of cluster headache with the serotonergic indoleamine psychedelics psilocybin and LSD and with ketamine: a case series. Cephalalgia Rep. 2025. https:\/\/doi.org\/10.1177\/25158163251345472.","journal-title":"Cephalalgia Rep"},{"issue":"2","key":"2339_CR80","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1080\/13554794.2018.1468469","volume":"24","author":"V Ramachandran","year":"2018","unstructured":"Ramachandran V, Chunharas C, Marcus Z, Furnish T, Lin A. Relief from intractable phantom pain by combining psilocybin and mirror visual-feedback (MVF). Neurocase. 2018;24(2):105\u201310.","journal-title":"Neurocase"},{"issue":"7-9","key":"2339_CR81","first-page":"37","volume":"20","author":"DW Lawrence","year":"2023","unstructured":"Lawrence DW. Self-administration of psilocybin for the acute treatment of migraine: a case report. Innov Clin Neurosci. 2023;20(7\u20139):37.","journal-title":"Innov Clin Neurosci"},{"key":"2339_CR82","doi-asserted-by":"publisher","DOI":"10.1177\/02698811251324372","author":"Z Bjurenfalk","year":"2025","unstructured":"Bjurenfalk Z, Cosmo A, Simonsson O, Ran C. Lifetime classic psychedelic use and headaches: a cross-sectional study. J Psychopharmacol. 2025. https:\/\/doi.org\/10.1177\/02698811251324372.","journal-title":"J Psychopharmacol"},{"issue":"1","key":"2339_CR83","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1007\/s13311-020-00962-y","volume":"18","author":"EAD Schindler","year":"2021","unstructured":"Schindler EAD, Sewell RA, Gottschalk CH, Luddy C, Flynn LT, Lindsey H, et al. Exploratory controlled study of the migraine-suppressing effects of psilocybin. Neurotherapeutics. 2021;18(1):534\u201343.","journal-title":"Neurotherapeutics"},{"issue":"10","key":"2339_CR84","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1111\/head.14420","volume":"62","author":"EAD Schindler","year":"2022","unstructured":"Schindler EAD, Sewell RA, Gottschalk CH, Luddy C, Flynn LT, Zhu Y, et al. Exploratory investigation of a patient-informed low-dose psilocybin pulse regimen in the suppression of cluster headache: results from a randomized, double-blind, placebo-controlled trial. Headache. 2022;62(10):1383\u201394.","journal-title":"Headache"},{"issue":"460","key":"2339_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2024.122993","volume":"15","author":"EAD Schindler","year":"2024","unstructured":"Schindler EAD, Sewell RA, Gottschalk CH, Flynn LT, Zhu Y, Pittman BP, et al. Psilocybin pulse regimen reduces cluster headache attack frequency in the blinded extension phase of a randomized controlled trial. J Neurol Sci. 2024;15(460):122993.","journal-title":"J Neurol Sci"},{"issue":"10","key":"2339_CR86","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1111\/head.14837","volume":"64","author":"J Rucker","year":"2024","unstructured":"Rucker J, Butler M, Hambleton S, Bird C, Seynaeve M, Cheema S, et al. Low-dose psilocybin in short-lasting unilateral neuralgiform headache attacks: results from an open-label phase Ib ascending dose study. Headache. 2024;64(10):1309\u201317.","journal-title":"Headache"},{"issue":"1","key":"2339_CR87","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1089\/psymed.2024.0011","volume":"3","author":"DJ Kruger","year":"2025","unstructured":"Kruger DJ, Aday JS, Fields CW, Kolbman N, Glynos N, Barron J, et al. Psychedelic therapist sexual misconduct and other adverse experiences among a sample of naturalistic psychedelic users. Psychedelic Med. 2025;3(1):41\u20137. https:\/\/doi.org\/10.1089\/psymed.2024.0011.","journal-title":"Psychedelic Med"},{"issue":"2","key":"2339_CR88","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1021\/acsptsci.1c00014","volume":"4","author":"JS Aday","year":"2021","unstructured":"Aday JS, Davis AK, Mitzkovitz CM, Bloesch EK, Davoli CC. Predicting reactions to psychedelic drugs: a systematic review of states and traits related to acute drug effects. ACS Pharmacol Transl Sci. 2021;4(2):424\u201335.","journal-title":"ACS Pharmacol Transl Sci."},{"issue":"3","key":"2339_CR89","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1177\/02698811211069100","volume":"36","author":"AK Schlag","year":"2022","unstructured":"Schlag AK, Aday J, Salam I, Neill JC, Nutt DJ. Adverse effects of psychedelics: from anecdotes and misinformation to systematic science. J Psychopharmacol. 2022;36(3):258\u201372.","journal-title":"J Psychopharmacol"},{"issue":"1","key":"2339_CR90","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1177\/02698811231215420","volume":"38","author":"L Bouchet","year":"2024","unstructured":"Bouchet L, Sager Z, Yrondi A, Nigam KB, Anderson BT, Ross S, et al. Older adults in psychedelic-assisted therapy trials: a systematic review. J Psychopharmacol. 2024;38(1):33\u201348.","journal-title":"J Psychopharmacol"},{"key":"2339_CR91","doi-asserted-by":"crossref","unstructured":"Aday JS, Carhart-Harris RL, Boehnke KF. Blunted psychedelic drug effects in older adults. Am J Geriatr Psychiatry. 2026.","DOI":"10.31234\/osf.io\/yz4cd_v2"},{"issue":"1","key":"2339_CR92","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jagp.2022.08.007","volume":"31","author":"CB Johnston","year":"2023","unstructured":"Johnston CB, Mangini M, Grob C, Anderson B. The safety and efficacy of psychedelic-assisted therapies for older adults: knowns and unknowns. Am J Geriatr Psychiatry. 2023;31(1):44\u201353.","journal-title":"Am J Geriatr Psychiatry"},{"key":"2339_CR93","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.neuropharm.2018.05.012","volume":"142","author":"MW Johnson","year":"2018","unstructured":"Johnson MW, Griffiths RR, Hendricks PS, Henningfield JE. The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Neuropharmacology. 2018;142:143\u201366.","journal-title":"Neuropharmacology"},{"issue":"9752","key":"2339_CR94","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/S0140-6736(10)61462-6","volume":"376","author":"DJ Nutt","year":"2010","unstructured":"Nutt DJ, King LA, Phillips LD. Drug harms in the UK: a multicriteria decision analysis. Lancet. 2010;376(9752):1558\u201365.","journal-title":"Lancet"},{"key":"2339_CR95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/00224499.2025.2479197","volume":"28","author":"DJ Kruger","year":"2025","unstructured":"Kruger DJ, Argyri EK, Mogilski JK, Herberholz M, Barron J, Aday JS, et al. Perceived impact of psychedelics on sexual, gender, and intimate relationship dynamics: a mixed-methods investigation. J Sex Res. 2025;28:1\u201312.","journal-title":"J Sex Res"},{"key":"2339_CR96","unstructured":"Aday JS, Glynos N, Baker A, Pouyan N, Barron J, Herberholz M, et al. Major life changes following psychedelic use: a retrospective survey among people using psychedelics naturalistically [Preprint]. 2024."},{"key":"2339_CR97","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.genhosppsych.2025.12.009","volume":"98","author":"ML Williams","year":"2026","unstructured":"Williams ML, Hitchcock K, Miller AH, Beck SA. Eligibility for psychedelic therapy: Clinical trial medical exclusion criteria and their implications for hospital practice. Gen Hosp Psychiatry. 2026;98:116\u201325.","journal-title":"Gen Hosp Psychiatry"},{"key":"2339_CR98","doi-asserted-by":"publisher","first-page":"943","DOI":"10.3389\/fpsyt.2019.00943","volume":"10","author":"JJ Fuentes","year":"2019","unstructured":"Fuentes JJ, Fonseca F, Elices M, Farre M, Torrens M. Therapeutic use of LSD in psychiatry: a systematic review of randomized-controlled clinical trials. Front Psychiatry. 2019;10:943.","journal-title":"Front Psychiatry"},{"issue":"5","key":"2339_CR99","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.bpsc.2024.01.007","volume":"9","author":"F Holze","year":"2024","unstructured":"Holze F, Singh N, Liechti ME, D\u2019Souza DC. Serotonergic psychedelics: a comparative review of efficacy, safety, pharmacokinetics, and binding profile. Biol Psychiatry Cogn Neurosci Neuroimaging. 2024;9(5):472\u201389. https:\/\/doi.org\/10.1016\/j.bpsc.2024.01.007.","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"issue":"12","key":"2339_CR100","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1001\/jamapsychiatry.2024.2546","volume":"81","author":"JT Hinkle","year":"2024","unstructured":"Hinkle JT, Graziosi M, Nayak SM, Yaden DB. Adverse events in studies of classic psychedelics: a systematic review and meta-analysis. JAMA Psychiat. 2024;81(12):1225\u201335.","journal-title":"JAMA Psychiat"},{"key":"2339_CR101","doi-asserted-by":"crossref","unstructured":"Thomann J, Kolaczynska KE, Stoeckmann OV, Rudin D, Vizeli P, Hoener MC, et al. In vitro and in vivo metabolism of psilocybin\u2019s active metabolite psilocin. Front Pharmacol. 2024;15.","DOI":"10.3389\/fphar.2024.1391689"},{"issue":"1","key":"2339_CR102","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/02698811231211219","volume":"38","author":"A Halman","year":"2024","unstructured":"Halman A, Kong G, Sarris J, Perkins D. Drug\u2013drug interactions involving classic psychedelics: a systematic review. J Psychopharmacol. 2024;38(1):3\u201318.","journal-title":"J Psychopharmacol"},{"issue":"2","key":"2339_CR103","first-page":"129","volume":"25","author":"LQ Guo","year":"2004","unstructured":"Guo LQ, Yamazoe Y. Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines. Acta Pharmacol Sin. 2004;25(2):129\u201336.","journal-title":"Acta Pharmacol Sin"},{"key":"2339_CR104","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.bcp.2019.04.013","volume":"164","author":"D Luethi","year":"2019","unstructured":"Luethi D, Hoener MC, Kr\u00e4henb\u00fchl S, Liechti ME, Duthaler U. Cytochrome P450 enzymes contribute to the metabolism of LSD to nor-LSD and 2-oxo-3-hydroxy-LSD: Implications for clinical LSD use. Biochem Pharmacol. 2019;164:129\u201338.","journal-title":"Biochem Pharmacol"},{"issue":"13","key":"2339_CR105","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1038\/s41386-023-01609-0","volume":"48","author":"I Straumann","year":"2023","unstructured":"Straumann I, Ley L, Holze F, Becker AM, Klaiber A, Wey K, et al. Acute effects of MDMA and LSD co-administration in a double-blind placebo-controlled study in healthy participants. Neuropsychopharmacology. 2023;48(13):1840\u20138.","journal-title":"Neuropsychopharmacology"},{"key":"2339_CR106","doi-asserted-by":"crossref","unstructured":"Blackwell B. Hypertensive crisis due to monoamine-oxidase inhibitors. 1963.","DOI":"10.1016\/S0140-6736(63)92743-0"},{"issue":"3","key":"2339_CR107","first-page":"99","volume":"57","author":"DM Gardner","year":"1996","unstructured":"Gardner DM, Shulman KI, Walker SE, Tailor S. The making of a user friendly MAOI diet. J Clin Psychiatry. 1996;57(3):99\u2013104.","journal-title":"J Clin Psychiatry"},{"key":"2339_CR108","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.886408","volume":"13","author":"I Berlowitz","year":"2022","unstructured":"Berlowitz I, Egger K, Cumming P. Monoamine oxidase inhibition by plant-derived \u03b2-carbolines; implications for the psychopharmacology of tobacco and Ayahuasca. Front Pharmacol. 2022;13:886408.","journal-title":"Front Pharmacol"},{"issue":"2","key":"2339_CR109","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.tips.2023.12.007","volume":"45","author":"F Reed","year":"2024","unstructured":"Reed F, Foldi CJ. Do the therapeutic effects of psilocybin involve actions in the gut? Trends Pharmacol Sci. 2024;45(2):107\u201317.","journal-title":"Trends Pharmacol Sci"},{"key":"2339_CR110","doi-asserted-by":"crossref","unstructured":"Meshkat S, Al-Shamali H, Perivolaris A, Tullu T, Zeifman RJ, Zhang Y, et al. Pharmacokinetics of psilocybin: a systematic review. Pharmaceutics. 2025;17(4).","DOI":"10.3390\/pharmaceutics17040411"},{"issue":"3","key":"2339_CR111","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/s41386-020-00883-6","volume":"46","author":"F Holze","year":"2021","unstructured":"Holze F, Vizeli P, Ley L, M\u00fcller F, Dolder P, Stocker M, et al. Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacology. 2021;46(3):537\u201344.","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"2339_CR112","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/cpt.2487","volume":"111","author":"AM Becker","year":"2022","unstructured":"Becker AM, Holze F, Grandinetti T, Klaiber A, Toedtli VE, Kolaczynska KE, et al. Acute effects of psilocybin after escitalopram or placebo pretreatment in a randomized, double-blind, placebo-controlled, crossover study in healthy subjects. Clin Pharmacol Ther. 2022;111(4):886\u201395.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"2339_CR113","doi-asserted-by":"publisher","first-page":"e13822","DOI":"10.1111\/psyp.13822","volume":"58","author":"S Olbrich","year":"2021","unstructured":"Olbrich S, Preller KH, Vollenweider FX. LSD and ketanserin and their impact on the human autonomic nervous system. Psychophysiology. 2021;58(6):e13822.","journal-title":"Psychophysiology"},{"key":"2339_CR114","doi-asserted-by":"publisher","first-page":"e35082","DOI":"10.7554\/eLife.35082","volume":"7","author":"KH Preller","year":"2018","unstructured":"Preller KH, Burt JB, Ji JL, Schleifer CH, Adkinson BD, St\u00e4mpfli P, et al. Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor. Elife. 2018;7:e35082.","journal-title":"Elife"},{"issue":"10","key":"2339_CR115","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1162\/089892905774597191","volume":"17","author":"OL Carter","year":"2005","unstructured":"Carter OL, Burr DC, Pettigrew JD, Wallis GM, Hasler F, Vollenweider FX. Using psilocybin to investigate the relationship between attention, working memory, and the serotonin 1A and 2A receptors. J Cogn Neurosci. 2005;17(10):1497\u2013508.","journal-title":"J Cogn Neurosci"},{"issue":"17","key":"2339_CR116","doi-asserted-by":"publisher","first-page":"3897","DOI":"10.1097\/00001756-199812010-00024","volume":"9","author":"FX Vollenweider","year":"1998","unstructured":"Vollenweider FX, Vollenweider-Scherpenhuyzen MF, B\u00e4bler A, Vogel H, Hell D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. NeuroReport. 1998;9(17):3897\u2013902.","journal-title":"NeuroReport"},{"issue":"1\u20132","key":"2339_CR117","first-page":"229","volume":"73","author":"KR Bonson","year":"1996","unstructured":"Bonson KR, Murphy DL. Alterations in responses to LSD in humans associated with chronic administration of tricyclic antidepressants, monoamine oxidase inhibitors or lithium. Behav Brain Res. 1996;73(1\u20132):229\u201333.","journal-title":"Behav Brain Res"},{"issue":"3","key":"2339_CR118","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s00213-004-2095-0","volume":"179","author":"JJ Balsara","year":"2005","unstructured":"Balsara JJ, Jadhav SA, Gaonkar RK, Gaikwad RV, Jadhav JH. Effects of the antidepressant trazodone, a 5-HT 2A\/2C receptor antagonist, on dopamine-dependent behaviors in rats. Psychopharmacology. 2005;179(3):597\u2013605.","journal-title":"Psychopharmacology"},{"issue":"12","key":"2339_CR119","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1007\/s40263-012-0010-5","volume":"26","author":"A Fagiolini","year":"2012","unstructured":"Fagiolini A, Comandini A, Dell\u2019Osso MC, Kasper S. Rediscovering trazodone for the treatment of major depressive disorder. CNS Drugs. 2012;26(12):1033\u201349.","journal-title":"CNS Drugs"},{"issue":"4","key":"2339_CR120","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1001\/archneurpsyc.1957.02330340026002","volume":"77","author":"H Isbell","year":"1957","unstructured":"Isbell H, Logan CR. Studies on the diethylamide of lysergic acid (LSD-25). II. Effects of chlorpromazine, azacyclonol, and reserpine on the intensity of the LSD-reaction. AMA Arch Neurol Psychiatry. 1957;77(4):350\u20138.","journal-title":"AMA Arch Neurol Psychiatry"},{"issue":"3","key":"2339_CR121","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/cpt196233314","volume":"1962","author":"HB Murphree","year":"1962","unstructured":"Murphree HB. Quantitative studies in humans on the antagonism of lysergic acid diethylamide by chlorpromazine and phenoxybenzamine. Clin Pharmacol Ther. 1962;1962(3):314\u201320.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"2339_CR122","first-page":"307","volume":"1960","author":"HA Abramson","year":"1960","unstructured":"Abramson HA, Rolo A, Stache J. Lysergic acid diethylamide (LSD-25) antagonists: chlorpromazine. J Neuropsychiatr. 1960;1960(1):307\u201310.","journal-title":"J Neuropsychiatr"},{"issue":"4","key":"2339_CR123","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/S0033-3182(67)71980-5","volume":"8","author":"CJ Schwarz","year":"1967","unstructured":"Schwarz CJ. Paradoxical responses to chiorpromazine after LSD. Psychosomatics. 1967;8(4):210\u20131.","journal-title":"Psychosomatics"},{"issue":"1","key":"2339_CR124","first-page":"66","volume":"3","author":"MH Keeler","year":"1967","unstructured":"Keeler MH. Chlorpromazine antagonism of psilocybin effect. Int J Neuropsychiatry. 1967;3(1):66.","journal-title":"Int J Neuropsychiatry"},{"issue":"2","key":"2339_CR125","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1097\/00005053-195808000-00004","volume":"127","author":"S Lesse","year":"1958","unstructured":"Lesse S. Psychodynamic relationships between the degree of anxiety and other clinical symptoms. J Nerv Ment Dis. 1958;127(2):124\u201330.","journal-title":"J Nerv Ment Dis"},{"issue":"4","key":"2339_CR126","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.euroneuro.2016.01.005","volume":"26","author":"T Pokorny","year":"2016","unstructured":"Pokorny T, Preller KH, Kraehenmann R, Vollenweider FX. Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A\/2A agonist ergotamine on psilocybin-induced psychedelic experience. Eur Neuropsychopharmacol. 2016;26(4):756\u201366.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"3","key":"2339_CR127","first-page":"241","volume":"7","author":"RJ Strassman","year":"1992","unstructured":"Strassman RJ. Human hallucinogen interactions with drugs affecting serotonergic neurotransmission. Neuropsychopharmacology. 1992;7(3):241\u20133.","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"2339_CR128","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/S0361-9230(01)00623-2","volume":"56","author":"JA Gray","year":"2001","unstructured":"Gray JA, Roth BL. Paradoxical trafficking and regulation of 5-HT(2A) receptors by agonists and antagonists. Brain Res Bull. 2001;56(5):441\u201351.","journal-title":"Brain Res Bull"},{"issue":"5","key":"2339_CR129","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/S0165-6147(00)01682-5","volume":"22","author":"F Artigas","year":"2001","unstructured":"Artigas F, Celada P, Laruelle M, Adell A. How does pindolol improve antidepressant action? Trends Pharmacol Sci. 2001;22(5):224\u20138.","journal-title":"Trends Pharmacol Sci"},{"issue":"10","key":"2339_CR130","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1038\/s41386-023-01648-7","volume":"48","author":"GM Goodwin","year":"2023","unstructured":"Goodwin GM, Croal M, Feifel D, Kelly JR, Marwood L, Mistry S, et al. Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication. Neuropsychopharmacology. 2023;48(10):1492\u20139.","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"2339_CR131","doi-asserted-by":"publisher","first-page":"10851","DOI":"10.1038\/s41598-021-90343-y","volume":"11","author":"P Vizeli","year":"2021","unstructured":"Vizeli P, Straumann I, Holze F, Schmid Y, Dolder PC, Liechti ME. Genetic influence of CYP2D6 on pharmacokinetics and acute subjective effects of LSD in a pooled analysis. Sci Rep. 2021;11(1):10851.","journal-title":"Sci Rep"},{"issue":"Suppl 5","key":"2339_CR132","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1097\/00004850-199809005-00009","volume":"13","author":"K Br\u00f8sen","year":"1998","unstructured":"Br\u00f8sen K. Differences in interactions of SSRIs. Int Clin Psychopharmacol. 1998;13(Suppl 5):S45\u20137.","journal-title":"Int Clin Psychopharmacol"},{"issue":"3","key":"2339_CR133","first-page":"306","volume":"7","author":"S Grof","year":"1965","unstructured":"Grof S, Dytrych Z. Blocking of LSD reaction by premedication with Niamid. Act Nerv Super. 1965;7(3):306.","journal-title":"Act Nerv Super"},{"issue":"1","key":"2339_CR134","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/cpt19601123","volume":"1","author":"EWJ DeMaar","year":"1960","unstructured":"DeMaar EWJ, Williams HL, Miller AI, Pfeiffer CC. Effects in man of single and combined oral doses of reserpine, iproniazid, and D-lysergic acid diethylamide. Clin Pharmacol Ther. 1960;1(1):23\u201330.","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"2339_CR135","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/0006-2952(80)90169-0","volume":"29","author":"SA Barker","year":"1980","unstructured":"Barker SA, Monti JA, Christian ST. Metabolism of the hallucinogen N,N-dimethyltryptamine in rat brain homogenates. Biochem Pharmacol. 1980;29(7):1049\u201357.","journal-title":"Biochem Pharmacol"},{"key":"2339_CR136","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/BF00405249","volume":"4","author":"A Sai Halasz","year":"1963","unstructured":"Sai Halasz A. The effect of mao inhibition on the experimental psychosis induced by dimethyltryptamine. Psychopharmacologia. 1963;4:385\u20138.","journal-title":"Psychopharmacologia"},{"issue":"2","key":"2339_CR137","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.pharmthera.2004.03.002","volume":"102","author":"DJ McKenna","year":"2004","unstructured":"McKenna DJ. Clinical investigations of the therapeutic potential of ayahuasca: rationale and regulatory challenges. Pharmacol Ther. 2004;102(2):111\u201329.","journal-title":"Pharmacol Ther"},{"issue":"4","key":"2339_CR138","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/j.1600-0773.1980.tb02459.x","volume":"46","author":"MM Airaksinen","year":"1980","unstructured":"Airaksinen MM, Svensk H, Tuomisto J, Komulainen H. Tetrahydro-beta-carbolines and corresponding tryptamines: In vitro inhibition of serotonin and dopamine uptake by human blood platelets. Acta Pharmacol Toxicol (Copenh). 1980;46(4):308\u201313.","journal-title":"Acta Pharmacol Toxicol (Copenh)."},{"issue":"6","key":"2339_CR139","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1093\/jat\/30.6.406","volume":"30","author":"JC Callaway","year":"2006","unstructured":"Callaway JC, Grob CS, McKenna DJ, Nichols DE, Shulgin A, Tupper KW. A demand for clarity regarding a case report on the ingestion of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in an Ayahuasca preparation. J Anal Toxicol. 2006;30(6):406\u20137 (author reply 7).","journal-title":"J Anal Toxicol"},{"issue":"2","key":"2339_CR140","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1081\/CLT-120030949","volume":"42","author":"DE Brush","year":"2004","unstructured":"Brush DE, Bird SB, Boyer EW. Monoamine oxidase inhibitor poisoning resulting from Internet misinformation on illicit substances. J Toxicol Clin Toxicol. 2004;42(2):191\u20135.","journal-title":"J Toxicol Clin Toxicol"},{"issue":"8","key":"2339_CR141","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1093\/jat\/29.8.838","volume":"29","author":"J Sklerov","year":"2005","unstructured":"Sklerov J, Levine B, Moore KA, King T, Fowler D. A fatal intoxication following the ingestion of 5-methoxy-N,N-dimethyltryptamine in an ayahuasca preparation. J Anal Toxicol. 2005;29(8):838\u201341.","journal-title":"J Anal Toxicol"},{"issue":"422","key":"2339_CR142","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1192\/bjp.101.422.12","volume":"101","author":"N Agnew","year":"1955","unstructured":"Agnew N, Hoffer A. Nicotinic acid modified lysergic acid diethylamide psychosis. J Ment Sci. 1955;101(422):12\u201327.","journal-title":"J Ment Sci"},{"issue":"3","key":"2339_CR143","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1124\/jpet.108.141333","volume":"327","author":"D Papaliodis","year":"2008","unstructured":"Papaliodis D, Boucher W, Kempuraj D, Michaelian M, Wolfberg A, House M, et al. Niacin-induced \u201cflush\u201d involves release of prostaglandin D2 from mast cells and serotonin from platelets: evidence from human cells in vitro and an animal model. J Pharmacol Exp Ther. 2008;327(3):665\u201372.","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"2339_CR144","doi-asserted-by":"publisher","first-page":"E14","DOI":"10.1176\/appi.neuropsych.12090212","volume":"25","author":"T Loebl","year":"2013","unstructured":"Loebl T, Raskin S. A novel case report: acute manic psychotic episode after treatment with niacin. J Neuropsychiatry Clin Neurosci. 2013;25(4):E14.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"6","key":"2339_CR145","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/sj.bjp.0707253","volume":"151","author":"PK Gillman","year":"2007","unstructured":"Gillman PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol. 2007;151(6):737\u201348.","journal-title":"Br J Pharmacol"},{"issue":"5","key":"2339_CR146","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1055\/a-1524-2794","volume":"54","author":"SM Nayak","year":"2021","unstructured":"Nayak SM, Gukasyan N, Barrett FS, Erowid E, Erowid F, Griffiths RR. Classic psychedelic coadministration with lithium, but not lamotrigine, is associated with seizures: an analysis of online psychedelic experience reports. Pharmacopsychiatry. 2021;54(5):240\u20135.","journal-title":"Pharmacopsychiatry"},{"key":"2339_CR147","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1176\/ajp.119.9.843","volume":"119","author":"DX Freedman","year":"1963","unstructured":"Freedman DX. Psychotomimetic drugs and brain biogenic amines. Am J Psychiatry. 1963;119:843\u201350.","journal-title":"Am J Psychiatry"},{"key":"2339_CR148","volume-title":"Reserpine (archived). StatPearls","author":"M Cheung","year":"2025","unstructured":"Cheung M, Parmar M. Reserpine (archived). StatPearls. Treasure Island: StatPearls Publishing; 2025."},{"key":"2339_CR149","doi-asserted-by":"crossref","unstructured":"O'Math\u00fana B, Farr\u00e9 M, Rostami-Hodjegan A, Yang J, Cuy\u00e0s E, Torrens M, et al. The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans. J Clin Psychopharmacol. 2008;28(5):523\u20139.","DOI":"10.1097\/JCP.0b013e318184ff6e"},{"issue":"7","key":"2339_CR150","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/1099-1077(200010)15:7<559::AID-HUP230>3.0.CO;2-J","volume":"15","author":"SP Barrett","year":"2000","unstructured":"Barrett SP, Archambault J, Engelberg MJ, Pihl RO. Hallucinogenic drugs attenuate the subjective response to alcohol in humans. Hum Psychopharmacol. 2000;15(7):559\u201365.","journal-title":"Hum Psychopharmacol"},{"key":"2339_CR151","volume":"23","author":"DS Sem","year":"2016","unstructured":"Sem DS. Co-developing drugs with indigenous communities: lessons from Peruvian law and the ayahuasca patent dispute. Rich JL & Tech. 2016;23:1.","journal-title":"Rich JL & Tech"},{"key":"2339_CR152","first-page":"1","volume":"4","author":"JS Aday","year":"2024","unstructured":"Aday JS, Bloesch EK, Davis AK, Domoff SE, Scherr K, Woolley JD, et al. Effects of Ayahuasca on gratitude and relationships with nature: a prospective naturalistic study. J Psychoactive Drugs. 2024;4:1\u201310.","journal-title":"J Psychoactive Drugs"},{"issue":"3","key":"2339_CR153","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.yrtph.2011.01.006","volume":"59","author":"J Van Amsterdam","year":"2011","unstructured":"Van Amsterdam J, Opperhuizen A, van den Brink W. Harm potential of magic mushroom use: a review. Regul Toxicol Pharmacol. 2011;59(3):423\u20139.","journal-title":"Regul Toxicol Pharmacol"},{"key":"2339_CR154","doi-asserted-by":"crossref","unstructured":"Liechti ME, Gasser P, Aicher HD, Mueller F, Hawrot T, Schmid Y. Implementing psychedelic-assisted therapy: History and characteristics of the Swiss limited medical use program. Neurosci Appl. 2025:105525.","DOI":"10.1016\/j.nsa.2025.105525"},{"key":"2339_CR155","doi-asserted-by":"crossref","unstructured":"Gr\u00fcnder G, Mertens LJ, Jungaberle A, Jungaberle H, Spangemacher M. Compassionate use of psilocybin for treatment-resistant depression in Germany. Lancet Psychiatry. 2025.","DOI":"10.1016\/S2215-0366(25)00277-9"},{"key":"2339_CR156","doi-asserted-by":"publisher","DOI":"10.1177\/2050324519872284","volume":"5","author":"JS Aday","year":"2019","unstructured":"Aday JS, Davoli CC, Bloesch EK. 2018: a watershed year for psychedelic science. Drug Sci Policy Law. 2019;5:2050324519872284.","journal-title":"Drug Sci Policy Law"},{"issue":"18","key":"2339_CR157","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","volume":"387","author":"GM Goodwin","year":"2022","unstructured":"Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, Bennett JC, et al. Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med. 2022;387(18):1637\u201348.","journal-title":"N Engl J Med"},{"issue":"6","key":"2339_CR158","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2022.1618","volume":"3","author":"KF Boehnke","year":"2022","unstructured":"Boehnke KF, Davis AK, McAfee J. Applying lessons from cannabis to the psychedelic highway: buckle up and build infrastructure. JAMA Health Forum. 2022;3(6):e221618.","journal-title":"JAMA Health Forum."},{"issue":"1","key":"2339_CR159","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1001\/jamapsychiatry.2022.4101","volume":"80","author":"JS Siegel","year":"2023","unstructured":"Siegel JS, Daily JE, Perry DA, Nicol GE. Psychedelic drug legislative reform and legalization in the US. JAMA Psychiat. 2023;80(1):77\u201383.","journal-title":"JAMA Psychiat"},{"key":"2339_CR160","unstructured":"The White House. Accelerating medical treatments for serious mental illness. 2026."},{"issue":"3","key":"2339_CR161","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1089\/psymed.2023.0013","volume":"1","author":"JS Aday","year":"2023","unstructured":"Aday JS, Barnett BS, Grossman D, Murnane KS, Nichols CD, Hendricks PS. Psychedelic commercialization: a wide-spanning overview of the emerging psychedelic industry. Psychedelic Med. 2023;1(3):150\u201365.","journal-title":"Psychedelic Med"},{"issue":"9","key":"2339_CR162","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1080\/17512433.2021.1933434","volume":"14","author":"SD Muthukumaraswamy","year":"2021","unstructured":"Muthukumaraswamy SD, Forsyth A, Lumley T. Blinding and expectancy confounds in psychedelic randomized controlled trials. Expert Rev Clin Pharmacol. 2021;14(9):1133\u201352.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"6","key":"2339_CR163","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1007\/s00213-022-06123-7","volume":"239","author":"JS Aday","year":"2022","unstructured":"Aday JS, Heifets BD, Pratscher SD, Bradley E, Rosen R, Woolley JD. Great Expectations: recommendations for improving the methodological rigor of psychedelic clinical trials. Psychopharmacology. 2022;239(6):1989\u20132010.","journal-title":"Psychopharmacology"},{"issue":"10","key":"2339_CR164","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1038\/s44220-024-00321-2","volume":"2","author":"L Colloca","year":"2024","unstructured":"Colloca L, Fava M. What should constitute a control condition in psychedelic drug trials? Nat Ment Health. 2024;2(10):1152\u201360.","journal-title":"Nat Ment Health."},{"key":"2339_CR165","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyaf023","author":"JS Aday","year":"2025","unstructured":"Aday JS, Simonsson O, Schindler EA, D\u2019Souza DC. Addressing blinding in classic psychedelic studies with innovative active placebos. Int J Neuropsychopharmacol. 2025. https:\/\/doi.org\/10.1093\/ijnp\/pyaf023.","journal-title":"Int J Neuropsychopharmacol"},{"key":"2339_CR166","first-page":"1","volume":"11","author":"NG Glynos","year":"2022","unstructured":"Glynos NG, Fields CW, Barron J, Herberholz M, Kruger DJ, Boehnke KF. Naturalistic psychedelic use: a world apart from clinical care. J Psychoactive Drugs. 2022;11:1\u201310.","journal-title":"J Psychoactive Drugs"},{"key":"2339_CR167","doi-asserted-by":"publisher","first-page":"1224551","DOI":"10.3389\/fpsyt.2023.1224551","volume":"14","author":"KF Boehnke","year":"2023","unstructured":"Boehnke KF, Cox K, Weston C, Herberholz M, Glynos N, Kolbman N, et al. Slouching towards engagement: interactions between people using psychedelics naturalistically and their healthcare providers. Front Psychiatry. 2023;14:1224551.","journal-title":"Front Psychiatry."},{"issue":"5","key":"2339_CR168","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1080\/02791072.2023.2242353","volume":"55","author":"NG Glynos","year":"2023","unstructured":"Glynos NG, Kruger DJ, Kolbman N, Boehnke K, Lucas P. The relationship between naturalistic psychedelic use and clinical care in Canada. J Psychoactive Drugs. 2023;55(5):660\u201371.","journal-title":"J Psychoactive Drugs"},{"key":"2339_CR169","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/02791072.2025.2491381","volume":"22","author":"NG Glynos","year":"2025","unstructured":"Glynos NG, Reid MR, Aday JS, Kruger DJ, Boehnke KF, Lake S, et al. Racial differences in naturalistic psychedelic use\u2014motivations for use, communication with health care providers, and outcomes. J Psychoactive Drugs. 2025;22:1\u201312.","journal-title":"J Psychoactive Drugs"},{"key":"2339_CR170","doi-asserted-by":"publisher","DOI":"10.7326\/ANNALS-24-03145","author":"KM Rockhill","year":"2025","unstructured":"Rockhill KM, Black JC, Ladka MS, Sumbundu KB, Olsen HA, Jewell JS, et al. The rise of psilocybin use in the United States: a multisource observational study. Ann Intern Med. 2025. https:\/\/doi.org\/10.7326\/ANNALS-24-03145.","journal-title":"Ann Intern Med"},{"issue":"10","key":"2339_CR171","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/jac5.1841","volume":"6","author":"K Herkenham","year":"2023","unstructured":"Herkenham K. A regulatory framework review of Schedule I psychedelics in the United States. J Am Coll Clin Pharm. 2023;6(10):1117\u201324.","journal-title":"J Am Coll Clin Pharm."},{"issue":"2","key":"2339_CR172","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1136\/annrheumdis-2016-209724","volume":"76","author":"GJ Macfarlane","year":"2017","unstructured":"Macfarlane GJ, Kronisch C, Dean LE, Atzeni F, H\u00e4user W, Flu\u00df E, et al. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis. 2017;76(2):318\u201328.","journal-title":"Ann Rheum Dis"},{"key":"2339_CR173","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2021.645246","volume":"12","author":"I Gorman","year":"2021","unstructured":"Gorman I, Nielson EM, Molinar A, Cassidy K, Sabbagh J. Psychedelic harm reduction and integration: a transtheoretical model for clinical practice. Front Psychol. 2021;12:645246.","journal-title":"Front Psychol"},{"issue":"3","key":"2339_CR174","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1080\/02791072.2020.1737763","volume":"52","author":"RL Lancelotta","year":"2020","unstructured":"Lancelotta RL, Davis AK. Use of benefit enhancement strategies among 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) users: associations with mystical, challenging, and enduring effects. J Psychoactive Drugs. 2020;52(3):273\u201381.","journal-title":"J Psychoactive Drugs"},{"key":"2339_CR175","volume-title":"The psychedelic explorer's guide: safe, therapeutic, and sacred journeys","author":"J Fadiman","year":"2011","unstructured":"Fadiman J. The psychedelic explorer\u2019s guide: safe, therapeutic, and sacred journeys. New York: Simon and Schuster; 2011."},{"issue":"1","key":"2339_CR176","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13034-025-00930-4","volume":"19","author":"S Forsberg","year":"2025","unstructured":"Forsberg S, Downey AE, Bruett LD, Hail L, Fernandes-Osterhold G, Woolley JD, et al. Leveraging family and caregiver support in psychedelic-assisted therapy: considerations for the treatment of adolescents. Child Adolesc Psychiatry Ment Health. 2025;19(1):64.","journal-title":"Child Adolesc Psychiatry Ment Health"},{"key":"2339_CR177","doi-asserted-by":"publisher","first-page":"103","DOI":"10.4324\/9781003167976-6","volume-title":"A somatic approach to psychedelic-assisted therapy. Integral psychedelic therapy","author":"V Gold","year":"2023","unstructured":"Gold V. A somatic approach to psychedelic-assisted therapy. Integral psychedelic therapy. Milton Park: Routledge; 2023. p. 103\u201327."},{"issue":"1","key":"2339_CR178","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-50612-3","volume":"9","author":"L Smigielski","year":"2019","unstructured":"Smigielski L, Kometer M, Scheidegger M, Kr\u00e4henmann R, Huber T, Vollenweider FX. Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat. Sci Rep. 2019;9(1):14914.","journal-title":"Sci Rep"},{"key":"2339_CR179","doi-asserted-by":"crossref","unstructured":"Thal S, Engel LB, Bright SJ. Presence, trust, and empathy: Preferred characteristics of psychedelic carers. J Humanistic Psychology. 2022:00221678221081380.","DOI":"10.1177\/00221678221081380"},{"issue":"1","key":"2339_CR180","first-page":"1","volume":"6","author":"SL Russ","year":"2019","unstructured":"Russ SL, Carhart-Harris RL, Maruyama G, Elliott MS. States and traits related to the quality and consequences of psychedelic experiences. Psychol Conscious Theor Res Pract. 2019;6(1):1.","journal-title":"Psychol Conscious Theor Res Pract"},{"issue":"3","key":"2339_CR181","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1093\/jmt\/thaa006","volume":"57","author":"C O\u2019Callaghan","year":"2020","unstructured":"O\u2019Callaghan C, Hubik DJ, Dwyer J, Williams M, Ross M. Experience of music used with psychedelic therapy: a rapid review and implications. J Music Ther. 2020;57(3):282\u2013314.","journal-title":"J Music Ther"},{"issue":"1","key":"2339_CR182","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41398-021-01335-5","volume":"11","author":"N Mason","year":"2021","unstructured":"Mason N, Kuypers K, Reckweg J, M\u00fcller F, Tse D, Da Rios B, et al. Spontaneous and deliberate creative cognition during and after psilocybin exposure. Transl Psychiatry. 2021;11(1):209.","journal-title":"Transl Psychiatry"},{"issue":"6","key":"2339_CR183","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1007\/s00213-022-06083-y","volume":"239","author":"A Sarparast","year":"2022","unstructured":"Sarparast A, Thomas K, Malcolm B, Stauffer CS. Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review. Psychopharmacology Berl. 2022;239(6):1945\u201376.","journal-title":"Psychopharmacology Berl"},{"key":"2339_CR184","doi-asserted-by":"crossref","unstructured":"Watts R. Psilocybin for depression: the ACE model manual. 2021.","DOI":"10.31234\/osf.io\/5x2bu"},{"issue":"1","key":"2339_CR185","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40337-024-01005-z","volume":"12","author":"AE Downey","year":"2024","unstructured":"Downey AE, Chaphekar AV, Woolley J, Raymond-Flesch M. Psilocybin therapy and anorexia nervosa: a narrative review of safety considerations for researchers and clinicians. J Eat Disord. 2024;12(1):49.","journal-title":"J Eat Disord"},{"issue":"6","key":"2339_CR186","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1177\/0269881108093587","volume":"22","author":"M Johnson","year":"2008","unstructured":"Johnson M, Richards W, Griffiths R. Human hallucinogen research: guidelines for safety. J Psychopharmacol. 2008;22(6):603\u201320.","journal-title":"J Psychopharmacol"},{"key":"2339_CR187","doi-asserted-by":"publisher","first-page":"1369715","DOI":"10.3389\/fpsyg.2024.1369715","volume":"15","author":"OC Robinson","year":"2024","unstructured":"Robinson OC, Evans J, Luke D, McAlpine R, Sahely A, Fisher A, et al. Coming back together: a qualitative survey study of coping and support strategies used by people to cope with extended difficulties after the use of psychedelic drugs. Front Psychol. 2024;15:1369715.","journal-title":"Front Psychol"},{"issue":"1","key":"2339_CR188","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1001\/jamapsychiatry.2021.2669","volume":"79","author":"YK Ashar","year":"2022","unstructured":"Ashar YK, Gordon A, Schubiner H, Uipi C, Knight K, Anderson Z, et al. Effect of pain reprocessing therapy vs placebo and usual care for patients with chronic back pain: a randomized clinical trial. JAMA Psychiat. 2022;79(1):13\u201323.","journal-title":"JAMA Psychiat"},{"issue":"8","key":"2339_CR189","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1007\/s00213-024-06620-x","volume":"241","author":"JS Aday","year":"2024","unstructured":"Aday JS, Horton D, Fernandes-Osterhold G, O\u2019Donovan A, Bradley ER, Rosen RC, et al. Psychedelic-assisted psychotherapy: where is the psychotherapy research? Psychopharmacology. 2024;241(8):1517\u201326.","journal-title":"Psychopharmacology"},{"issue":"15","key":"2339_CR190","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1001\/jama.2014.3266","volume":"311","author":"DJ Clauw","year":"2014","unstructured":"Clauw DJ. Fibromyalgia: a clinical review. JAMA. 2014;311(15):1547\u201355.","journal-title":"JAMA"},{"issue":"7","key":"2339_CR191","doi-asserted-by":"publisher","first-page":"493","DOI":"10.7326\/M16-2459","volume":"166","author":"R Chou","year":"2017","unstructured":"Chou R, Deyo R, Friedly J, Skelly A, Hashimoto R, Weimer M, et al. Nonpharmacologic therapies for low back pain: a systematic review for an American College of Physicians clinical practice guideline. Ann Intern Med. 2017;166(7):493\u2013505.","journal-title":"Ann Intern Med"},{"issue":"1","key":"2339_CR192","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1176\/appi.ajp.20221043","volume":"181","author":"GM Goodwin","year":"2024","unstructured":"Goodwin GM, Malievskaia E, Fonzo GA, Nemeroff CB. Must psilocybin always \u201cassist psychotherapy\u201d? Am J Psychiatry. 2024;181(1):20\u20135.","journal-title":"Am J Psychiatry"},{"key":"2339_CR193","doi-asserted-by":"crossref","unstructured":"Chen M-H, Cheng S-L, Kao Y-C, Tseng P-T, Hsu C-W, Yu C-L, et al. The association between diverse psychological protocols and the efficacy of psilocybin-assisted therapy for clinical depressive symptoms: a Bayesian meta-analysis. Front Psychiatry. 2024;15.","DOI":"10.3389\/fpsyt.2024.1439347"},{"issue":"1","key":"2339_CR194","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.54843","volume":"9","author":"GA Florineth","year":"2026","unstructured":"Florineth GA, Klima I, Boeker AL, Catzeflis P, Wopfner A, Denier N, et al. Psychological therapy quantity and depressive symptom reduction in psychedelic-assisted therapy: a systematic review and meta-analysis. JAMA Netw Open. 2026;9(1):e2554843.","journal-title":"JAMA Netw Open"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02339-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02339-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02339-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T12:02:07Z","timestamp":1784203327000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-026-02339-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":194,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["2339"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02339-5","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"17 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JSA was partially supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health (T32AR007080-44S1) as well as by the National Institute of Dental and Craniofacial Research under 5T90DE034663-02.","order":1,"name":"Ethics","label":"Funding","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"KFB has received grant funding from Tryp Therapeutics for a clinical trial of psilocybin-assisted therapy and sat on a data safety and monitoring board for an ongoing clinical trial with Vireo Health (unpaid). He has received grant funding from the National Institute on Drug Abuse, National Center for Complementary and Integrative Health, and the National Institutes of Arthritis, Musculoskeletal, and Skin Diseases of the National Institutes of Health. He has also received granting funding from the State of Michigan Veteran Marijuana Research Program. KFB has received speaking fees for lectures from the Southern Pain Society and the Michigan Center of Clinical Systems Improvement. He received an honorarium for developing a podcast on fibromyalgia with Viatris Inc. JSA was partially supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health (T32AR007080-44S1). JSA declares no other conflicts of interest. NP declares no conflicts of interest. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.","order":2,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent (participation and publication)","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors contributed to the conceptualization of this article. KFB led the initial drafting of the article with support from NP and JSA. All authors provided critical revisions. All authors read and approved the final version of this article.","order":5,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data sharing not applicable to this article as no datasets were generated or analysed during the current study.","order":6,"name":"Ethics","label":"Data availability statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}